Monday, September 16 (HealthDay News)-Medicines used for treatment Biting erythrocytosis In addition to reducing complications, new studies can reduce the medical costs associated with treating children affected by this painful condition.
A new cost-benefit analysis shows that the daily dose for treatment Hydroxyurea Less hospitalization and blood transfusion, pain.. They also had an average of $ 3,000 less medical costs than children who received standard treatment.
“In addition to alleviating humans suffering from sickle cell disease, we discovered it. Hydroxyurea Dr. James Casella, a research researcher and director of the Department of Pediatric Hematology at the Johns Hopkins Children’s Center, said in a Hopkins news release.
“Our main goal is to find better treatments, but this is really welcome news when trying to control medical costs while improving patient outcomes,” Casella added. ..
This disease is characterized by abnormalities Red blood cells It is C-shaped or “ill”.Due to their abnormal shape, these cells store oxygen, distribute it to the body mass within blood vessels, and block it. circulation..This can increase the risk stroke And infectious diseases.It can also be a serious cause anemia And extreme pain.. According to a news release, about 100,000 people in the United States have sickle cell disease.
Hydroxyurea is currently the only drug approved by the US Food and Drug Administration and pain It is associated with sickle cell disease.The drug takes an abnormal shape Red blood cells By increasing the level of typing, you are less likely to bend or harden hemoglobin..
The study was published online in the journal on September 2nd. PediatricsWe reviewed information on the hospitalization of 167 patients with sickle cell disease between the ages of 1 and 3. Specifically, we looked at how many times children were hospitalized between 2003 and 2009, and how much their medical costs were.
Half of the children included in the study were treated with hydroxyurea in addition pain Dosing and blood transfusion. The other half of the patients received standard treatment, but instead of hydroxyurea, they took the active ingredient-free placebopill.
Children treated with hydroxyurea were admitted to the hospital 232 times, the study showed. In contrast, patients who did not receive this drug were hospitalized 324 times.
The researchers also found that the average hospitalization cost for children who took hydroxyurea was $ 9,450, compared to $ 13,716 for children who were not treated with the drug.
Outpatient costs for children receiving hydroxyurea increased by $ 1,376 per year, but these high costs were offset by hospitalization and reduced complications. Overall, the average cost of treatment for children treated with hydroxyurea was $ 11,072. On the other hand, the overall average cost of treatment for those who did not take the drug was $ 13,962.
Researchers conclude that hydroxyurea should be used more often to treat people with sickle cell disease, and their findings suggest that more doctors include the drug in their treatment plans. He said it should be encouraged.
“Our analysis demonstrates the additional benefits of using hydroxyurea in the treatment of sickle cell disease associated with the effects of the drug on medical costs, and the drug in both children and adults. It should be another factor that supports the broader use of sickle cells, “Dr. Winfred One, senior researcher in the hematology department at St. Jude Children’s Research Hospital, said in a news release.
-Mary Elizabeth Dallas
Copyright © 2013 Health Day. all rights reserved.
Source: Johns Hopkins Medicine, News Release, September 11, 2013
Sickle cell disease medications reduce symptoms and reduce medical costs as well, research discovers
Source link Sickle cell disease medications reduce symptoms and reduce medical costs as well, research discovers